Literature DB >> 25589660

Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease.

Anurodh Shankar Agrawal1, Tania Garron1, Xinrong Tao1, Bi-Hung Peng2, Maki Wakamiya3, Teh-Sheng Chan1, Robert B Couch4, Chien-Te K Tseng5.   

Abstract

UNLABELLED: The emergence of Middle East respiratory syndrome-coronavirus (MERS-CoV) in the Middle East since 2012 has caused more than 900 human infections with ∼40% mortality to date. Animal models are needed for studying pathogenesis and for development of preventive and therapeutic agents against MERS-CoV infection. Nonhuman primates (rhesus macaques and marmosets) are expensive models of limited availability. Although a mouse lung infection model has been described using adenovirus vectors expressing human CD26/dipeptidyl peptidase 4 (DPP4), it is believed that a transgenic mouse model is needed for MERS-CoV research. We have developed this transgenic mouse model as indicated in this study. We show that transgenic mice globally expressing hCD26/DPP4 were fully permissive to MERS-CoV infection, resulting in relentless weight loss and death within days postinfection. High infectious virus titers were recovered primarily from the lungs and brains of mice at 2 and 4 days postinfection, respectively, whereas viral RNAs were also detected in the heart, spleen, and intestine, indicating a disseminating viral infection. Infected Tg(+) mice developed a progressive pneumonia, characterized by extensive inflammatory infiltration. In contrast, an inconsistent mild perivascular cuffing was the only pathological change associated with the infected brains. Moreover, infected Tg(+) mice were able to activate genes encoding for many antiviral and inflammatory mediators within the lungs and brains, coinciding with the high levels of viral replication. This new and unique transgenic mouse model will be useful for furthering knowledge of MERS pathogenesis and for the development of vaccine and treatments against MERS-CoV infection. IMPORTANCE: Small and economical animal models are required for the controlled and extensive studies needed for elucidating pathogenesis and development of vaccines and antivirals against MERS. Mice are the most desirable small-animal species for this purpose because of availability and the existence of a thorough knowledge base, particularly of genetics and immunology. The standard small animals, mice, hamsters, and ferrets, all lack the functional MERS-CoV receptor and are not susceptible to infection. So, initial studies were done with nonhuman primates, expensive models of limited availability. A mouse lung infection model was described where a mouse adenovirus was used to transfect lung cells for receptor expression. Nevertheless, all generally agree that a transgenic mouse model expressing the DPP4 receptor is needed for MERS-CoV research. We have developed this transgenic mouse model as indicated in this study. This new and unique transgenic mouse model will be useful for furthering MERS research.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589660      PMCID: PMC4403411          DOI: 10.1128/JVI.03427-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Viral induction of central nervous system innate immune responses.

Authors:  J D Rempel; L A Quina; P K Blakely-Gonzales; M J Buchmeier; D L Gruol
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

3.  Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized Calu-3 lung epithelial cells.

Authors:  Chien-Te K Tseng; Jennifer Tseng; Lucy Perrone; Melissa Worthy; Vsevolod Popov; Clarence J Peters
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.

Authors:  Susan R Weiss; Sonia Navas-Martin
Journal:  Microbiol Mol Biol Rev       Date:  2005-12       Impact factor: 11.056

5.  Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor.

Authors:  Chien-Te K Tseng; Cheng Huang; Patrick Newman; Nan Wang; Krishna Narayanan; Douglas M Watts; Shinji Makino; Michelle M Packard; Sherif R Zaki; Teh-Sheng Chan; Clarence J Peters
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

6.  Heterologous introns can enhance expression of transgenes in mice.

Authors:  R D Palmiter; E P Sandgren; M R Avarbock; D D Allen; R L Brinster
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

7.  Functional analysis of Gscl in the pathogenesis of the DiGeorge and velocardiofacial syndromes.

Authors:  M Wakamiya; E A Lindsay; J A Rivera-Pérez; A Baldini; R R Behringer
Journal:  Hum Mol Genet       Date:  1998-11       Impact factor: 6.150

8.  Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon.

Authors:  Luisa Cervantes-Barragan; Roland Züst; Friedemann Weber; Martin Spiegel; Karl S Lang; Shizuo Akira; Volker Thiel; Burkhard Ludewig
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

9.  A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice.

Authors:  Anjeanette Roberts; Damon Deming; Christopher D Paddock; Aaron Cheng; Boyd Yount; Leatrice Vogel; Brian D Herman; Tim Sheahan; Mark Heise; Gillian L Genrich; Sherif R Zaki; Ralph Baric; Kanta Subbarao
Journal:  PLoS Pathog       Date:  2007-01       Impact factor: 6.823

Review 10.  Severe acute respiratory syndrome.

Authors:  J S M Peiris; Y Guan; K Y Yuen
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

View more
  125 in total

1.  Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.

Authors:  Kristen E Pascal; Christopher M Coleman; Alejandro O Mujica; Vishal Kamat; Ashok Badithe; Jeanette Fairhurst; Charleen Hunt; John Strein; Alexander Berrebi; Jeanne M Sisk; Krystal L Matthews; Robert Babb; Gang Chen; Ka-Man V Lai; Tammy T Huang; William Olson; George D Yancopoulos; Neil Stahl; Matthew B Frieman; Christos A Kyratsous
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

2.  Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits.

Authors:  Bart L Haagmans; Judith M A van den Brand; Lisette B Provacia; V Stalin Raj; Koert J Stittelaar; Sarah Getu; Leon de Waal; Theo M Bestebroer; Geert van Amerongen; Georges M G M Verjans; Ron A M Fouchier; Saskia L Smits; Thijs Kuiken; Albert D M E Osterhaus
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice.

Authors:  Kun Li; Christine L Wohlford-Lenane; Rudragouda Channappanavar; Jung-Eun Park; James T Earnest; Thomas B Bair; Amber M Bates; Kim A Brogden; Heather A Flaherty; Tom Gallagher; David K Meyerholz; Stanley Perlman; Paul B McCray
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-27       Impact factor: 11.205

4.  Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection.

Authors:  Jincun Zhao; Ranawaka A P M Perera; Ghazi Kayali; David Meyerholz; Stanley Perlman; Malik Peiris
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

5.  Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.

Authors:  Lingshu Wang; Wei Shi; James D Chappell; M Gordon Joyce; Yi Zhang; Masaru Kanekiyo; Michelle M Becker; Neeltje van Doremalen; Robert Fischer; Nianshuang Wang; Kizzmekia S Corbett; Misook Choe; Rosemarie D Mason; Joseph G Van Galen; Tongqing Zhou; Kevin O Saunders; Kathleen M Tatti; Lia M Haynes; Peter D Kwong; Kayvon Modjarrad; Wing-Pui Kong; Jason S McLellan; Mark R Denison; Vincent J Munster; John R Mascola; Barney S Graham
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

6.  CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome.

Authors:  Christopher M Coleman; Jeanne M Sisk; Gabor Halasz; Jixin Zhong; Sarah E Beck; Krystal L Matthews; Thiagarajan Venkataraman; Sanjay Rajagopalan; Christos A Kyratsous; Matthew B Frieman
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

Review 7.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

8.  A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Authors:  Anna H Malczyk; Alexandra Kupke; Steffen Prüfer; Vivian A Scheuplein; Stefan Hutzler; Dorothea Kreuz; Tim Beissert; Stefanie Bauer; Stefanie Hubich-Rau; Christiane Tondera; Hosam Shams Eldin; Jörg Schmidt; Júlia Vergara-Alert; Yasemin Süzer; Janna Seifried; Kay-Martin Hanschmann; Ulrich Kalinke; Susanne Herold; Ugur Sahin; Klaus Cichutek; Zoe Waibler; Markus Eickmann; Stephan Becker; Michael D Mühlebach
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

Review 9.  Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus.

Authors:  Anthony R Fehr; Rudragouda Channappanavar; Stanley Perlman
Journal:  Annu Rev Med       Date:  2016-08-26       Impact factor: 13.739

Review 10.  Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.

Authors:  Yuhang Wang; Matthew Grunewald; Stanley Perlman
Journal:  Methods Mol Biol       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.